Literature DB >> 23531371

Microbiology and antimicrobial treatment of pediatric cervical lymphadenitis requiring surgical intervention.

Laura Neff1, Jason G Newland, Kevin J Sykes, Rangaraj Selvarangan, Julie L Wei.   

Abstract

BACKGROUND: Acute cervical lymphadenitis is a common condition often times requiring antibiotic therapy and possible surgical drainage. The objective of this study was to describe the clinical characteristics, diagnostic and therapeutic management of children requiring surgical drainage for acute cervical lymphadenitis.
METHODS: A retrospective, descriptive study was performed at a Midwestern US tertiary-care children's hospital on all immunocompetent children who underwent an incision and drainage procedure of cervical lymphadenitis from January 1999 to July 2009.
RESULTS: A total of 277 patients were identified. Males represented 51% and the median age was 28 months (IQR: 13-59). Lymphadenitis was unilateral in 243 (87.7%) cases and bilateral in 19 (6.9%). Median length of hospital stay was 4 days (IQR: 3-5). Aerobic, anaerobic, acid fast bacillus (AFB), and fungal cultures were obtained intraoperatively in 99%, 98%, 82%, and 78% of cases, respectively. However no fungal cultures were positive and only 1% of anaerobic and 2% of AFB cultures were positive. The most common bacterial etiology was Staphylococcus aureus (35.7%) and Streptococcus pyogenes (18.8%). Of all cultures, 32% were negative. Overall, 22% were positive for methicillin susceptible S. aureus (MSSA) and 13.7% for methicillin resistant S. aureus (MRSA), with 96% MSSA and 100% MRSA susceptible to clindamycin. Median duration of discharge antibiotics prescribed was 10 days (IQR: 7-11). Only 12 (4.5%) patients required a repeat incision and drainage within 3 months.
CONCLUSIONS: A single antibiotic that treats S. pyogenes and S. aureus should be the empiric antibiotic for cervical lymphadenitis requiring incision and drain. We recommend sending only aerobic cultures intraoperatively as a routine practice as other pathogens are rare.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23531371     DOI: 10.1016/j.ijporl.2013.02.018

Source DB:  PubMed          Journal:  Int J Pediatr Otorhinolaryngol        ISSN: 0165-5876            Impact factor:   1.675


  5 in total

1.  Cervical suppurative lymphadenitis in children: microbiology, primary sites of infection, and evaluation of antibiotic treatment.

Authors:  Nicolai Østergaard Nielsen; Christian Nørlinger; Thomas Greve; Tejs Ehlers Klug
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-10-08       Impact factor: 2.503

2.  Imaging Strategies and Outcomes in Children Hospitalized with Cervical Lymphadenitis.

Authors:  Sanyukta Desai; Samir S Shah; Matt Hall; Troy E Richardson; Joanna E Thomson
Journal:  J Hosp Med       Date:  2019-11-20       Impact factor: 2.960

Review 3.  Emerging and re-emerging infectious disease in otorhinolaryngology.

Authors:  F Scasso; G Ferrari; G C DE Vincentiis; A Arosio; S Bottero; M Carretti; A Ciardo; S Cocuzza; A Colombo; B Conti; A Cordone; M DE Ciccio; E Delehaye; L Della Vecchia; I DE Macina; C Dentone; P DI Mauro; R Dorati; R Fazio; A Ferrari; G Ferrea; S Giannantonio; I Genta; M Giuliani; D Lucidi; L Maiolino; G Marini; P Marsella; D Meucci; T Modena; B Montemurri; A Odone; S Palma; M L Panatta; M Piemonte; P Pisani; S Pisani; L Prioglio; A Scorpecci; L Scotto DI Santillo; A Serra; C Signorelli; E Sitzia; M L Tropiano; M Trozzi; F M Tucci; L Vezzosi; B Viaggi
Journal:  Acta Otorhinolaryngol Ital       Date:  2018-04       Impact factor: 2.124

4.  Paediatric acute lymphadenitis: Emergency department management and clinical course.

Authors:  Michelle Long; Deepti N Reddy; Salwa Akiki; Nicholas J Barrowman; Roger Zemek
Journal:  Paediatr Child Health       Date:  2019-09-21       Impact factor: 2.253

Review 5.  Cervical lymph node diseases in children.

Authors:  Stephan Lang; Benjamin Kansy
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2014-12-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.